Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced its strategy to secure 7.5 years of U.S. exclusivity for istaroxime, its investigational treatment for cardiogenic shock, if approved by the …
Windtree Therapeutics Unveils U.S. Exclusivity Strategy for Istaroxime Read More